Imunon is a clinical-stage biotechnology company developing non-viral DNA-based therapeutics that harness the body's natural immune system to treat cancer, infectious diseases, and other conditions. The company advances two primary technology platforms: TheraPlas, which encodes therapeutic proteins and cytokines for localized tumor immunotherapy, and PlaCCine, which encodes viral antigens for vaccine applications. Imunon's lead program is a DNA-based immunotherapy for advanced ovarian cancer in Phase 3 clinical development, while the company also pursues vaccine candidates across infectious disease indications. The company operates a manufacturing facility and is not currently generating product revenue, instead funding operations through equity offerings and seeking strategic partnerships and collaborative arrangements to advance its drug candidates toward regulatory approval and commercialization.